Criteria to qualify for study: Drug used in study:
  • Received 1-3 prior lines of therapy for AL Amyloidosis; Dflc>20 mg/L; bone marrow plasma cells <30%

AMY 09

A single arm, open-label, phase 1/2 study of ZN-dS for the treatment of relapsed or refractory light chain (AL) Amyloidosis.

AMY 09 Clinical Trial